OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis $48.27 0.00 (0.00%) As of 08/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesShort InterestBuy This Stock About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$48.27▼$48.2750-Day Range$47.56▼$56.9152-Week Range$45.97▼$59.26Volume239 shsAverage Volume723 shsMarket CapitalizationN/AP/E Ratio15.59Dividend Yield0.66%Price TargetN/AConsensus RatingN/A Company Overview Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom. Read More Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPY Stock News HeadlinesHikma Pharmaceuticals (HIK) Gets a Hold from BarclaysAugust 14, 2025 | theglobeandmail.comHikma Pharmaceuticals Executive Exercises Share OptionsAugust 13, 2025 | msn.comBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of the market’s most overlooked opportunities today. NanoViricides, Inc. (NYSE: NNVC) is advancing NV-387, a broad-spectrum antiviral now in human trials, with activity against COVID-19, RSV, influenza, measles, and most recently Mpox. With Phase II trials approved in Africa for the deadliest Mpox strain, the timing couldn’t be more critical.August 18 at 2:00 AM | Smallcaps Daily (Ad)Hikma Pharmaceuticals climbs Wednesday, outperforms marketAugust 13, 2025 | marketwatch.comHikma Pharmaceuticals rallies Monday, outperforms marketAugust 11, 2025 | marketwatch.comA $236bn growth opportunity!? Is this FTSE 100 stock about to skyrocket?August 11, 2025 | uk.finance.yahoo.comHikma Pharmaceuticals records 6% revenue growth in H1 2025 | Jordan TimesAugust 8, 2025 | msn.comHikma outlook cut for unit's margins clouds confidence in overall forecastsAugust 7, 2025 | reuters.comSee More Headlines HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed this year? Hikma Pharmaceuticals' stock was trading at $50.0075 at the beginning of 2025. Since then, HKMPY stock has decreased by 3.5% and is now trading at $48.27. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/18/2025Ex-Dividend for 9/29 Dividend8/18/2025Record date for 9/29 Dividend8/19/2025Dividend Payable9/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HKMPY CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,100Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio15.59 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:HKMPY) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.